Smoking and tardive dyskinesia in male patients with chronic schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1765-1769

  Zhang, Xiang Yang ^a,b   Yu, Ya Qin ^c   Sun, Shilong ^c   Zhang, Xuan ^c   Li, Wenjun ^c   Xiu, Mei Hong ^b   Chen, Da Chun ^b   De Yang, Fu ^b   Zhu, Fengyan ^b   Kosten, Therese A ^a   Kosten, Thomas R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BEIJING HUILONGGUAN HOSPITAL   (China)

^c JILIN UNIVERSITY   (China)

Author keywords

Antipsychotics; Nicotine; Schizophrenia; Smoking; Tardive dyskinesia

Indexed keywords

BENZATROPINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PERPHENAZINE; RISPERIDONE; SCOPOLAMINE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGE; AGED; ARTICLE; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MONOTHERAPY; NEUROLEPTIC MALIGNANT SYNDROME; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PREVALENCE; PSYCHOLOGIC ASSESSMENT; QUESTIONNAIRE; SCHIZOPHRENIA; SCORING SYSTEM; SMOKING; TARDIVE DYSKINESIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DYSKINESIA, DRUG-INDUCED; HUMANS; INPATIENTS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SINGLE-BLIND METHOD; SMOKING; TOBACCO; YOUNG ADULT;

EID: 79961129693     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.06.006     Document Type: Article

References (48)

1. Aia P.G., Revuelta G.J., Cloud L.J., Factor S.A. Tardive dyskinesia. Curr Treat Options Neurol 2011, 3(3):231-241.
2. Andersson K., Fuxe K., Agnati L.F., Eneroth P. Effects of acute central and peripheral administration of nicotine on ascending dopamine pathways in the male rat brain. Evidence for nicotine induced increases of dopamine turnover in various telencephalic dopamine nerve terminal systems. Med Biol 1981, 59(3):170-176.
3. Ballesteros J., Gonzalez-Pinto A., Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol 2000, 20:188-194.
4. Bassitt D.P., Louza Neto M.R. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. European archives of psychiatry and clinical neuroscience. Eur Arch Psychiatry Clin Neurosci 1998, 248(4):209-211.
5. Binder R.L., Kazamatsuri H., Nishimura T., McNiel D.E. Smoking and tardive dyskinesia. Biol Psychiatry 1987, 22:1280-1282.
6. Browne S., Roe M., Lane A., Gervin M., Morris M., Kinsella A., et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996, 94:118-124.
7. Chong S.A., Tan E.C., Tan C.H., Mythily Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 2003, 28:185-189.
8. Clarke P.B., Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res 1985, 348:355-358.
9. Clarke P.B., Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Research 1985, 348:355-358.
10. Correll C.U., Schenk E.M. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008, 21:151-156.
11. Correll C.U., Leucht S., Kane J.M. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004, 161:414-425.
12. de Jesus M.J., Razzouk D., Thara R., Eaton J., Thornicroft G. Packages of care for schizophrenia in low- and middle-income countries. PLoS Med. 2009, 6(10):e1000165.
13. de Leon J., Diaz F. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005, 76:135-157.
14. de Leon J., Becoña E., Gurpegui M., Gonzalez-Pinto A., Diaz F.J. The association between high nicotine dependence and severe mental illness may be consistent across countries. J Clin Psychiatry 2002, 63(9):812-816.
15. Diehl A., Reinhard I., Schmitt A., Mann K., Gattaz W.F. Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial. Eur Psychiatry 2009, 24:33-40.
16. Dilsaver S.C., Smeltzer D.J. Smoking and tardive dyskinesia. Biol Psychiatry 1988, 24(3):364.
17. Elbaz A., Moisan F. Update in the epidemiology of Parkinson's disease. Curr Opin Neurol 2008, 21:454-460.
18. Erdfelder E., Faul F., Buchner A. GPOWER: a general power analysis program. Behav Res Methods Instrum Comput 1996, 28:1-11.
19. Ghaemi S.N., Hsu D.J., Rosenquist K.J., Pardo T.B., Goodwin F.K. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 30:209-213.
20. Goff D.C., Henderson D.C., Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992, 149(9):1189-1194.
21. Hao W., Young D., Li L., Xiao S. Psychoactive substance use in three sites in China: gender differences and related factors. Psychiatry Clin Neurosci 1998, 52(Suppl):S324-S328.
22. Jann M.W., Ereshefsky L., Saklad S.R. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 1985, 10:315-333.
23. Jeste D.V. Tardive dyskinesia in older patients. J Clin Psychiatry 2000, 61(Suppl 4):27-32.
24. Jeste D.V. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry 2004, 65(Suppl 9):21-22.
25. Kane J.M. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004, 65(Suppl 9):6-20.
26. Kelly C., McCreadie R.G. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry 1999, 156:1751-1757.
27. Kirch D.G., Gerhardt G.A., Shelton R.C., Freedman R., Wyatt R.J. Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain. Clin Neuropharmacol 1987, 10:376-383.
28. Lee P.E., Sykora K., Gill S.S., Mamdani M., Marras C., Anderson G., et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 2005, 53:1374-1379.
29. Lee S., Guo W.J., Tsang A., Huang Y.Q., He Y.L., Kessler R.C. Prevalence and correlates of active and ever-smokers in metropolitan China. Addict Behav 2009, 34(11):969-972.
30. Lohr J.B., Kuczenski R., Niculescu A.B. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003, 17:47-62.
31. Menza M.A., Grossman N., Van Horn M., Cody R., Forman N. Smoking and movement disorders in psychiatric patients. Biol Psychiatry 1991, 30:109-115.
32. Nilsson A., Waller L., Rosengren A., Adlerberth A., Wilhelmsen L. Cigarette smoking is associated with abnormal involuntary movements in the general male population-a study of men born in 1933. Biol Psychiatry 1997, 41:717-723.
33. Quik M. Smoking, nicotine and Parkinson's disease. Trends Neurosci 2004, 27:561-568.
34. Rascol O., Fabre N. Dyskinesia: l-Dopa-induced and tardive dyskinesia. Clin Neuropharmacol 2001, 24:313-323.
35. Rasmussen K., Czachura J.F. Nicotine withdrawal leads to increased firing rates of midbrain dopamine neurons. Neuroreport 1995, 7:329-332.
36. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed?. Curr Opin Psychiatry 2007, 20:131-137.
37. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982, 39:486-487.
38. See R.E., Chapman M.A. The consequences of long-term antipsychotic drug administration on basal ganglia neuronal function in laboratory animals. Crit Rev Neurobiol 1994, 8:85-124.
39. Seeman P. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J Clin Psychopharmacol 1988, 8(4 Suppl):3S-9S.
40. Silvestri S., Negrete J.C., Seeman M.V., Shammi C.M., Seeman P. Does nicotine affect D2 receptor upregulation? A case-control study. Acta Psychiatr Scand 2004, 109:313-317.
41. Tang Y.L., Gillespie C.F., Epstein M.P., Mao P.X., Jiang F., Chen Q., et al. Gender differences in 542 Chinese inpatients with schizophrenia. Schizophr Res 2007, 97:88-96.
42. Tarsy D., Baldessarini R.J., Tarazi F.I. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002, 16:23-45.
43. Tarsy D., Lungu C., Baldessarini R.J. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handb Clin Neurol 2011, 100:601-616.
44. Thacker E.L., O'Reilly E.J., Weisskopf M.G., Chen H., Schwarzschild M.A., McCullough M.L., et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 2007, 68:764-768.
45. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003, 64(6):663-667.
46. Yassa R., Lal S., Korpassy A., Ally J. Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987, 22:67-72.
47. Youssef H.A., Waddington J.L. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand 1987, 75:74-77.
48. Zhang X.Y., Zhang R.L., Pan M., Chen D.C., Xiu M.H., Kosten T.R. Sex difference in the prevalence of smoking in Chinese schizophrenia. J Psychiatr Res 2010, 44:986-988.